Psychopharmacology: Substance Use and Eating Disorders

0.0(0)
Studied by 0 people
call kaiCall Kai
learnLearn
examPractice Test
spaced repetitionSpaced Repetition
heart puzzleMatch
flashcardsFlashcards
GameKnowt Play
Card Sorting

1/36

flashcard set

Earn XP

Description and Tags

Vocabulary flashcards covering the key diagnostic terms, neurobiological mechanisms, genetic architectures, and pharmacotherapeutic treatments for substance use and eating disorders.

37 Terms

1
New cards

Psychoactive Substance

Any chemical substance that acts upon the central nervous system to alter brain function, resulting in temporary changes in perception, mood, consciousness, and behavior.

2
New cards

Drug Dependence

The habitual consumption of a substance, which may involve physical dependence where the body neuroadapts to the drug, resulting in a distinct withdrawal syndrome upon cessation.

3
New cards

Substance Abuse

The use of any drug, typically self-administered, in ways that deviate from accepted social norms or medical guidelines.

4
New cards

Substance Misuse

The incorrect or improper use of medications that have been prescribed by healthcare professionals.

5
New cards

Addiction

A condition characterized by compulsive and escalating substance use, marked by distressing symptoms and overwhelming cravings during absence, as well as physical and psychological decline.

6
New cards

Substance Intoxication

A temporary condition induced by a substance that disrupts mental faculties such as memory, awareness, mood, judgment, and social or occupational functioning.

7
New cards

Withdrawal Syndrome

A cluster of physical and psychological symptoms (also termed abstinence or discontinuation syndrome) that emerges when an individual abruptly ceases or reduces chronic, heavy substance use.

8
New cards

Drug Tolerance

A state of decreased drug responsiveness after repeated administration, requiring progressively higher doses to achieve the initial pharmacological impact.

9
New cards

Behavioral Tolerance

An individual's acquired ability to perform motor and cognitive tasks successfully despite being under the active influence of a drug.

10
New cards

Cross-Tolerance (Cross-Dependence)

The phenomenon in which exposure to one drug produces tolerance or dependence to another drug that shares similar physiological and mental mechanisms of action (e.g., diazepam and barbiturates).

11
New cards

SUD Heritability

The proportion of total substance use disorder risk attributable to genetics, established by twin and adoption studies to be between 40%40\% and 60%60\%.

12
New cards

Polygenic Architecture

The genetic basis of addiction liability, which is driven by hundreds to thousands of small-effect genomic variants across the genome rather than a single causal gene.

13
New cards

CHRNA5-CHRNA3-CHRNB4 Cluster

A genomic cluster encoding nicotinic acetylcholine receptor subunits linked to nicotine dependence, accounting for a substance heritability of approximately 60%60\%.

14
New cards

ADH1B and ALDH2 Variants

Genomic variants in alcohol-metabolizing enzymes that provide protective metabolic effects against alcohol use disorder by accelerating acetaldehyde accumulation.

15
New cards

Mesolimbic Dopamine Pathway

The primary reward pathway extending from the ventral tegmental area (VTA) to the nucleus accumbens (NAc), which addictive drugs hijack to elevate synaptic dopamine levels up to 10 times higher than natural rewards.

16
New cards

The Three-Stage Addiction Cycle

A recurring neurobiological framework consisting of: 1) Binge/Intoxication (basal ganglia), 2) Withdrawal/Aversive state (extended amygdala), and 3) Preoccupation/Anticipation (prefrontal cortex).

<p>A recurring neurobiological framework consisting of: 1) Binge/Intoxication (basal ganglia), 2) Withdrawal/Aversive state (extended amygdala), and 3) Preoccupation/Anticipation (prefrontal cortex).</p>
17
New cards

Epigenetic Remodeling

Chemical modifications such as DNA methylation and histone acetylation induced by trauma, chronic stress, or substance use that alter gene transcription without modifying the underlying DNA sequence.

18
New cards

Incentive Salience ("Wanting")

A subconscious, dopamine-driven motivational urge that transforms neutral stimuli into attention-grabbing "motivational magnets" that compel reward-seeking behavior.

19
New cards

Hedonic Impact ("Liking")

The actual subjective feeling of sensory pleasure experienced during reward consumption, mediated by endogenous opioid and endocannabinoid networks rather than dopamine.

20
New cards

Incentive-Sensitization Theory

A theory developed by Kent Berridge and Terry Robinson positing that addiction results from neural sensitization of mesolimbic "wanting" pathways alongside tolerance-driven reductions in hedonic "liking."

21
New cards

Starvation-Induced Sensitization in Anorexia Nervosa

A misdirected survival mechanism where metabolic deprivation elevates dopamine signaling, attaching incentive salience to fasting, calorie deficits, and exercise instead of food cues.

22
New cards
<p>Ventral-to-Dorsal Striatal Shift</p>

Ventral-to-Dorsal Striatal Shift

The neurocircuitry transition from ventral striatal (NAc) impulsivity driven by positive reinforcement to dorsal striatal compulsivity driven by negative reinforcement and habit.

23
New cards

Tonic Dopamine Neurotransmission

Slow, steady pacemaker firing (1–8 Hz1\text{--}8\,\text{Hz}) that targets high-affinity dopamine D2D_2 receptors to maintain baseline mood, motivation, and executive flexibility.

24
New cards

Phasic Dopamine Neurotransmission

Rapid, synchronized burst firing (>15–30 Hz>15\text{--}30\,\text{Hz} for <500 ms<500\,\text{ms}) targeting low-affinity dopamine D1D_1 receptors to signal reward prediction errors and salient stimuli.

25
New cards

Varenicline

A first-line smoking cessation medication that acts as a selective α4β2\alpha_4\beta_2 nicotinic acetylcholine receptor partial agonist and antagonist, blunting reward and reducing cravings.

26
New cards

Bupropion SR

A first-line smoking cessation medication acting as a dopamine/norepinephrine reuptake inhibitor (NDRI) with weak nAChR antagonism; contraindicated in seizure and eating disorders.

27
New cards

Cytisinicline

A plant-derived alkaloid that functions as a selective partial agonist at α4β2\alpha_4\beta_2 nicotinic acetylcholine receptors, used as an emerging/regional treatment for smoking cessation.

28
New cards

Naltrexone

A competitive mu-opioid receptor antagonist that blunts alcohol-induced dopamine release and blocks opioid euphoria; contraindicated in acute liver failure or concurrent opioid use.

29
New cards

Acamprosate

A first-line oral medication for alcohol dependence that modulates glutamate (NMDA/mGluR5) and enhances GABA to alleviate protracted withdrawal; eliminated 100%100\% unchanged renally.

30
New cards

Disulfiram

A second-line aversive deterrent for alcohol use that irreversibly inhibits aldehyde dehydrogenase (ALDH), causing toxic acetaldehyde accumulation upon ethanol intake.

31
New cards

Topiramate

An off-label medication that enhances GABAAGABA_A receptors and inhibits AMPA/kainate receptors, reducing heavy drinking in alcohol use disorder as well as binging in bulimia and BED.

32
New cards

Baclofen

A selective GABABGABA_B receptor agonist that suppresses mesolimbic dopamine firing, used off-label to maintain abstinence in patients with advanced alcoholic liver disease or cirrhosis.

33
New cards

Methadone

A long-acting full mu-opioid receptor agonist and weak NMDA antagonist with no respiratory ceiling effect, used as a first-line maintenance treatment for severe opioid use disorder.

34
New cards

Buprenorphine

A high-affinity partial mu-opioid agonist and kappa-opioid antagonist that exhibits a ceiling effect on respiratory depression, requiring mild-to-moderate withdrawal before induction.

35
New cards

Lofexidine

A central α2\alpha_2-adrenergic agonist that blunts locus coeruleus hyperactivity to manage autonomic symptoms during acute opioid withdrawal.

36
New cards

Dual Diagnosis

The clinical condition in which an individual simultaneously meets diagnostic criteria for both a substance use disorder and a co-occurring psychiatric disorder.

37
New cards

Simultaneous Integrated Treatment

The clinical standard for dual diagnosis wherein both substance use and co-occurring psychiatric disorders are managed concurrently by the same multidisciplinary team.